# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Wells Fargo analyst Brandon Couillard maintains Danaher (NYSE:DHR) with a Equal-Weight and raises the price target from $205...
Thermo Fisher Scientific reports Q3 2025 adjusted earnings of $5.79 per share, sales of $11.12 billion and raised its full-year...
TD Cowen analyst Dan Brennan maintains Danaher (NYSE:DHR) with a Buy and raises the price target from $250 to $260.
Barclays analyst Luke Sergott maintains Danaher (NYSE:DHR) with a Overweight and raises the price target from $225 to $250.
Danaher Corporation (NYSE:DHR) shares are rising Tuesday after the company reported better-than-expected third-quarter financia...
Gold prices suffered a sharp correction on Tuesday as investors locked in profits following this year's explosive rally, wh...